
Abemaciclib: Different by Design



Continuous dosing schedule

Provides **uninterrupted inhibition** to prevent rebound and lead to cell death* (preclinical)

Can be taken every day, so patients can feel they are doing everything they can to delay the progression of their cancer



Blood-brain barrier crossing

Early data from phase II study demonstrated CNS response

CSF samples from phase I study were collected from a subset of patients and demonstrated that concentrations of Abemaciclib in CSF were generally consistent with the unbound plasma concentrations



Distinct safety profile

With a minority of patients experiencing grade 3 or above neutropenia (less than 1/3)

With 9 to 20% of patients experiencing grade 3 or above diarrhea

Only CDK4 & 6 inhibitor that has demonstrated single agent activity and provides the flexibility to meet the needs of patients at more points in their journey

SINGLE _

Only CDK4/6 approved as monotherapy

Consistent Benefit in harder to treat population

- Higher magnitude of benefit in hard to treat population.
- Statistically well-designed subgroup analysis.

